| | 460738-38-9 Basic information More.. |
| Product Name: | ecallantide | | Synonyms: | ecallantide;DX 88;ecallantide USP/EP/BP;Cys16-Cys40;Cys32-Cys53);H-Glu-Ala-Met-His-Ser-Phe-Cys-Ala-Phe-Lys-Ala-Asp-Asp-Gly-Pro-Cys-Arg-Ala-Ala-His-Pro-Arg-Trp-Phe-Phe-Asn-Ile-Phe-Thr-Arg-Gln-Cys-Glu-Glu-Phe-Ile-Tyr-Gly-Gly-Cys-Glu-Gly-Asn-Gln-Asn-Arg-Phe-Glu-Ser-Leu-Glu-Glu-Cys-Lys-Lys-Met-Cys-Thr-Arg-Asp-OH(Disulfide bridge：Cys7-Cys57 | | CAS: | 460738-38-9 | | MF: | C305H442N88O91S8 | | MW: | 7053.82798 | | EINECS: | | | Mol File: | 460738-38-9.mol |  |
Use
Ecallantide, also known as DX-88, was approved in 2009 in the
United States for treatment of hereditary angioedema (HAE), a condition
characterized by episodic attacks of localized edema in cutaneous
and mucosal tissues. HAE results from deficiencies or disorders of C1-esterase inhibitor protein (C1-
1NH). Mutation of the gene that encodes C1-1NH causes the lack or
altered activity of the serine protease, C1-1NH. C1-1NH regulates the
kallikrein–kinin (contact activation) and complement cascade systems.
Ecallantide (DX-88) was designed to inhibit the action of
plasma kallikrein. Ecallantide is a potent and selective inhibitor of
plasma kallikrein with a Ki= 25 pM. The discovery program that
identified ecallantide used phage display technology and a library of
designed variants of the first Kunitz domain of TFPI. Ecallantide, a
60-amino acid peptide, with 3-disulfide bonds, differs from TFPI by
7-amino acids. Ecallantide has been developed as a subcutaneous
administered formulation.
- Ecallantide
-
- US $0.00 / g
- 2025-05-27
- CAS:460738-38-9
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
- Ecallantide
-
- US $0.00-0.00 / mg
- 2025-04-28
- CAS:460738-38-9
- Min. Order:
- Purity:
- Supply Ability: 10g
- ecallantide
-
- US $10.00 / kg
- 2024-03-08
- CAS:460738-38-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
|
|
460738-38-9
Recommend Suppliers |
|